CellWell record HH-435155
Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial
Stine Ulrik Mikkelsen; Ali Al-Mousawi; Amalie Bach Puglisi; Anders Pommer Vallentin; Astrid Østergaard Mortensen; Zachary Madaj; Toshinori Hinoue; Heidi Naomi Ottesen; Jakob Schmidt Jespersen; Linn Gillberg; Morten Tulstrup; Niels Richard Hansen; Jakob Werner Hansen; Mette Klarskov Andersen; Stacey Lyn Thomas; Christine Isaguirre; Ryan Sheldon; Marie Adams; Ryan Burgos; Stephen Baylin; Bo Kok Mortensen; Casey Lee O'Connell; Marianne Tang Severinsen; Peter William Laird; Jens Lykkesfeldt; Peter Jones; Kirsten Grønbæk
2026
In plain language
In a randomized trial of 109 adults with clonal cytopenia or lower-risk myeloid malignancy, oral ascorbate did not alter clonal growth, but was associated with fewer serious adverse events and, in exploratory analysis, longer survival.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-435155
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.